Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Bin Yang, MD, PhD, is a Staff in the Pathology and Laboratory Medicine Institute of the Cleveland Clinic. He is the Medical Director of Molecular Cytopathology and Director of Cancer Epigenetics Core Laboratory in the Department of Anatomic Pathology. Dr. Yang is clinically specialized in gynecologic pathology and diagnostic cytopathology including fine needle aspiration service.
Dr. Yang is also an expertise in molecular pathology with focus on translation of advanced molecular techniques into disease detection and prognostic monitoring. His research interests are in two areas: 1) Application of advanced molecular techniques for early detection of cancer cells in cytologic materials, such as PAP smears and urine; and 2) Application of advanced molecular techniques in prediction of chemosensitivity in gynecologic cancers such as ovarian cancer. From technical point of view, analyzing the methylation profiling of tumor suppressor genes is the primary focus of his research.
Dr. Yang's study on DNA methylation profiling of a set of tumor suppressor genes has achieved prominent progress by identifying some interesting biomarkers differentially methylated in different dysplastic stages of cervical cancer. Their study has been recognized recently as the annual meeting of the American Society of Cytopathology in Houston and has been awarded "The Geno Saccomanno New Frontiers of Cytology Award" in November 2007. He is the only recipient who was awarded twice for this prestigious award.
He was the President of the Chinese American Pathologist Association, a professional organization which has 300+ pathologists with Chinese ethnic background. Currently he is the consultant pathologist for the Preventive Oncology International and consultant in Sino-US Cervical Cancer Programs of under-served areas in China. Dr. Yang has given numerous speeches and presentations as invited speaker at the national and international conferences.
Bin Yang received his M.D. in Zhengzhou University School of Medicine in China in 1983, his Ph.D. training in Molecular Biology under supervision of Dr. Sanford Markowitz, an investigator at the Howard Houghes Medical Institutions at the Case Western Reserve University in 1996. He finished his pathology residency training in 2000 at the Cleveland Clinic, his surgical pathology fellowship training in 2001 at the Washington University in St. Louis, and his cytopathology fellowship and molecular pathology training in 2003 at the Johns Hopkins Medical Institutions in Baltimore.
Cytopathology, Gynecologic pathology, fine needle aspiration, Molecular Pathology
Innovations & Patents
We have successfully filed a US patent with a title of "Detection of urothelial carcinoma in urine using DNA methylation profiling of tumor suppressor genes." (US utility patent #05136). Our study showed that using DNA methylation profiling, the sensitivity in detection of low grade bladder urothelial carcinoma is increased from 20% by cytomorphology alone to 85% using molecular approaches.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/17/2016, Dr. Yang has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.